Danute M. Bankaitis-Davis
Keine laufenden Positionen mehr
Profil
Danute M.
Bankaitis-Davis worked as a Research Scientist at Amgen, Inc. from 1992 to 1998.
She also worked as a Principal at Syntex Corp.
and as an Executive Vice President at Source Precision Medicine, Inc. Dr. Bankaitis-Davis received her undergraduate and graduate degrees from Cleveland State University and her doctorate degree from The University of North Carolina at Charlotte.
Ehemalige bekannte Positionen von Danute M. Bankaitis-Davis
| Unternehmen | Position | Ende |
|---|---|---|
| AMGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 |
| Syntex Corp. | Corporate Officer/Principal | - |
Source Precision Medicine, Inc.
 Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Corporate Officer/Principal | - |
Ausbildung von Danute M. Bankaitis-Davis
| The University of North Carolina at Charlotte | Doctorate Degree |
| Cleveland State University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Source Precision Medicine, Inc.
Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Health Technology |
| Syntex Corp. | Health Technology |
